April 2020

April 14, 2020

How has treating infections changed with the availability of experimental vaccines and therapeutics, and how can we apply this to COVID-19 today?

April 13, 2020

Outcomes in disseminated nocardiosis are variable and depend on patient factors.

April 10, 2020

Funded jurisdictions scramble to meet daunting deadlines yet maintain optimism that the new federal initiative can end flat funding and catalyze progress.

April 09, 2020

IDSA reached its goal, but nobody’s buying. Can the drowning antimicrobial pipeline be saved?

April 08, 2020

Infections caused by non–carbapenemase-producing carbapenem-resistant Enterobacteriaceae present challenges in the treatment paradigm. Given the limited clinical data, the preferred therapeutic approach remains unknown.

April 07, 2020

To better support the use of critical antibiotics, the Centers for Medicare & Medicaid Services revised the rules governing reimbursement for qualifying antibiotic products. For these changes to succeed, hospital systems will need to make adjustments.

April 06, 2020

With advancements in antiretroviral therapy, people with HIV are now living longer and developing age-related chronic conditions.

April 03, 2020

Interests have recently skewed toward the use of carbapenem-sparing regimens in light of growing selection for carbapenem-resistant organisms.

April 02, 2020

Christina Tan, MD, MPH, from the New Jersey Department of Health discusses COVID-19.

April 01, 2020

COVID-19 does not present our first pandemic, nor will it be our last. What should we take note of?